Effective planning begins with grading VMS severity, characterizing the sleep complaint, and confirming hormone therapy ...

Limited visit time, minimal sleep medicine training, and widespread self-medication leave many women with menopause-related ...

The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults ...

Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 ...

One question at every visit could prevent strokes in atrial fibrillation, says Geoffrey Barnes, MD, who also previews ...

Annual injections, every-4-month dosing, and a once-monthly pill could reshape HIV prevention. Yet the faculty agree the most ...

Linda Bradley, MD, explains why blind endometrial sampling may miss focal uterine pathology and when persistent abnormal ...

Insights from The Menopause Society 2026 Annual Meeting on underdiagnosis, night sweat red flags, and what to tell patients starting a nonhormonal therapy.

October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart ...

Black and Hispanic women had higher rates of hormone therapy discontinuation in a new study. Intira Sriprasert, MD, PhD, ...

Sleep disturbance is often the most bothersome symptom of the menopause transition, yet it frequently goes unreported unless ...

JoAnn Pinkerton, MD, discusses elinzanetant's onset of VMS relief, common adverse effects, and treatment expectations for ...